Mini iPads Could Be A Mega Apple Hit [View article]
You are absolutely right on your comments. The $150 million of incremental profit refers only to Q1 earnings (Nov-Dec 2012). iPad mini's potential will reach far beyond 2012. We are working on a report on AAPL's stock valuation and will integrate the revenue growth of its products into 5-year projection.
Lipitor's Patent Expiration: How Much Will It Impact Pfizer's Revenue And Earnings In 2012? [View article]
If you read any of the big pharma's annual reports, you will find that they all have dozens of litigation or lawsuits going on all the time. The costs have become part of their operating expense and have been factored in our valuation model. We will have a final valuation report for Pfizer out soon. Stay tuned.
Lipitor's Patent Expiration: How Much Will It Impact Pfizer's Revenue And Earnings In 2012? [View article]
We will post another report on Pfizer's valuation. We think its fair value is $27-28. So, there is not a great upside from here. If you are looking another pharma stock to replace Pfizer, we would recommend JNJ (Johnson and Johnson). Its current fair value is $81 and likely to continue to go up, based on our analysis. Please read our JNJ piece at Seeking Alpha:
Johnson & Johnson Stock Valuation - Part 4 [View article]
It's hard to guess how the market will behave in the near term. But a correction of 5% or more is possible. JNJ will report Q3 earnings in October. The earnings may not look good, given the $350M Alzheimer drug write-off. So, there may be a buying opportunity. I would think a price below $65 is a good starting point.
Johnson & Johnson Stock Valuation - Part 4 [View article]
There are several ways to assess a company's management. One is to look at their financial performance. The other is to listen or read annual report to gauge their business strategies and how well they execute those strategies. If you suspect that management is not doing a good job, then you could also assign higher required rate of return (r) in the valuation model. In essence, a higher r suggests a greater business risk and brings down the company's value.
Johnson & Johnson - Life After The Patent Cliff? [View article]
Glad to hear that Yervoy works for you. Indeed, immunotherapy like Yervoy is a revolutionary therapy in cancer field. We would expect BMY to expand Yervoy to other cancer types. In addition, BMY is developing another cancer immunotherapy (anti-PD1) similar to Yervoy. We will write reports on BMY and on cancer immunotherapies in general. Please keep an eye on our reports.
Is Amarin Positioned To Be A Takeover Target? [View article]
If the company needs to fund the trial by issuing more common stocks, it will increase outstanding share counts. As a result, the current shareholders percentage of ownership will be reduced. We have seen cases where a company issued 30% more of its stock, and the stock price plunged 20%.
Johnson & Johnson Stock Valuation - Part 1 [View article]
Nice observation. I think NVS has started its innovation years ahead of JNJ, which may explain its superior run over 10-year period. JNJ has recognized this in 2009 with their pledge to launch 11 products between 2011 and 2015. We believe those new drugs will contribute to sustained growth in the future.
In order for a prescription drug to be marketed in a country, it requires the approval from the country's regulatory agency. Since Amarin's AMR101 is approved by FDA, it can be marketed in the US. If AMR101 also gets approval by the EMA, then it can be sold in European countries. Another important factor is patent protection. Without patent protection, other companies can make me-too products and take away market shares. To be conservative in our valuation, we only use the US sales figures in the estimates.
Mini iPads Could Be A Mega Apple Hit [View article]
Lipitor's Patent Expiration: How Much Will It Impact Pfizer's Revenue And Earnings In 2012? [View article]
Lipitor's Patent Expiration: How Much Will It Impact Pfizer's Revenue And Earnings In 2012? [View article]
http://seekingalpha.co...
Johnson & Johnson Stock Valuation - Part 4 [View article]
Johnson & Johnson Stock Valuation - Part 4 [View article]
Johnson & Johnson Stock Valuation - Part 4 [View article]
Johnson & Johnson Stock Valuation - Part 4 [View article]
Johnson & Johnson - Life After The Patent Cliff? [View article]
http://seekingalpha.co...
http://seekingalpha.co...
Johnson & Johnson - Life After The Patent Cliff? [View article]
Is Amarin Positioned To Be A Takeover Target? [View article]
Is Amarin Positioned To Be A Takeover Target? [View article]
Johnson & Johnson Stock Valuation - Part 1 [View article]
Johnson & Johnson Stock Valuation - Part 1 [View article]
Amarin Valuation Before FDA Action [View article]
Amarin Valuation Before FDA Action [View article]